Back to top
more

Integra LifeSciences (IART)

(Real Time Quote from BATS)

$25.95 USD

25.95
214,793

-0.75 (-2.81%)

Updated Nov 7, 2024 12:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?

by Zacks Equity Research

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) is expected to have gained from continued strength in Clear Aligner shipment volumes in Q2.

Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

The rest of businesses within Life-Science Solutions segment of Thermo Fisher (TMO) are likely to have registered strong quarterly growth led by genetic sciences and bio production businesses.

Integra Reports Organic Sales Drop in Preliminary Q2 Results

by Zacks Equity Research

Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.

Urmimala Biswas headshot

Medical Instruments Outlook Dull Amid Coronavirus Crisis

by Urmimala Biswas

Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.

Integra (IART) Up 8.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook

by Zacks Equity Research

Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Integra LifeSciences (IART) Misses Q1 Earnings Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of -20.00% and 0.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Reports Next Week: What to Know Ahead of the Release

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain HealthEquity Stock for Now

by Zacks Equity Research

Investor confidence remains high in HealthEquity (HQY) stock, thanks to solid prospects.

Bio-Rad Launches Serology Test to Detect Coronavirus Antibody

by Zacks Equity Research

Bio-Rad (BIO) launches a blood-based immunoassay kit to better detect antibodies in response to SARS-CoV-2 infection.

Why Integra (IART) Could Beat Earnings Estimates Again

by Zacks Equity Research

Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Integra Releases Preliminary Q1 Results, Withdraws '20 View

by Zacks Equity Research

Integra (IART) unable to measure the magnitude of total loss it has to bear out of the coronavirus-led economic damages, and hence, withdraws the full-year guidance.

Merit Medical WRAPSODY Gets 2 FDA Breakthrough Device Nods

by Zacks Equity Research

This regulatory clearance is expected to bolster Merit Medical Systems' (MMSI) cardiovascular segment.

Here's Why You Should Retain AMN Healthcare (AMN) for Now

by Zacks Equity Research

Investor confidence remains high on AMN Healthcare's (AMN) stock, thanks to solid prospects.

Here's Why You Should Add Surmodics to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high in Surmodics' (SRDX) stock,thanks to solid prospects.

Zacks.com featured highlights include: TGNA, IART, PCG, CLGX and ABC

by Zacks Equity Research

Zacks.com featured highlights include: TGNA, IART, PCG, CLGX and ABC

Varian Unveils Proton Treatment Planning Eclipse v16 System

by Zacks Equity Research

The launch of this system is a step forward in Varian's (VAR) commitment toward strengthening its Proton Solutions segment.

Urmimala Biswas headshot

5 Recession-Proof PEG Picks Suitable for GARP Investors

by Urmimala Biswas

Here are five GARP stocks to brace your portfolio from recessionary hurdles.

Here's Why You Should Add DexCom (DXCM) to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high in DexCom's (DXCM) stock, thanks to solid prospects.

Syneos Health Launches Initiative for COVID-19 Patients

by Zacks Equity Research

The primary aim of this initiative by Syneos Health (SYNH) is to address the predicted ventilator deficiency in the wake of the coronavirus pandemic.

IART vs. ABMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

IART vs. ABMD: Which Stock Is the Better Value Option?

Stellar Codman Surgical Sales Aid Integra Amid Supply Issues

by Zacks Equity Research

Completion of integration activities, scale expansion, product launches, and venturing into faster-growing markets drive Interga's (IART) sales within Codman Surgical.

Why Is Integra (IART) Down 37.3% Since Last Earnings Report?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Buy Integra LifeSciences Stock Now

by Zacks Equity Research

Investor confidence is high in Integra LifeSciences (IART) stock, thanks to solid prospects.